The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A national treatment survey on the chemotherapy (CTX) treatment for patients (Pts) with metastatic breast cancer (MBC) in Germany.
Christian Jackisch
Consultant or Advisory Role - Roche
Michael Untch
No relevant relationships to disclose
Peter Dall
No relevant relationships to disclose
Christoph Thomssen
No relevant relationships to disclose
Ute-Susann Albert
No relevant relationships to disclose
Hans-Joachim Lueck
Honoraria - Celgene; Novartis; Roche
Ingo Bauerfeind
Honoraria - Bristol-Myers Squibb; Celgene; Eisai; Roche
Anton J. Scharl
No relevant relationships to disclose